Different Incidence of Acute Kidney Injury In Adult Patients Receiving Different types Extracorporeal Membrane Oxygenation: A Meta-Analysis

Zhixiang Mou, M.D.

Correspondence: zm330053@rwth-aachen.de; Tel.: (+8613702075820)

Abstract: Background: Acute kidney injury (AKI) has been reported as one of the most common complication in patients receiving extracorporeal membrane oxygenation (ECMO), the incidence of AKI on different types ECMO is unclear. This meta-analysis aimed to compare the AKI incidence among adult patients requiring different modes of ECMO. Methods: A literature search was performed using several databases fulfilled the pre-specified criteria until March 2020 to include studies reported the interested clinic result, then the meta- analysis was performed by STATA to get conclusion. Results: the estimated incidence of AKI and severe AKI requiring RRT were both higher in VA ECMO patients than in VV ECMO patients.

Keywords: AKI; extracorporeal membrane oxygenation; ECMO; ECLS; incidence

---

1. Introduction

Extracorporeal membrane oxygenation (ECMO) is a rescue therapy used for patients with severe cardiac and/or pulmonary failure [1]. There has been a rapidly increased in the usage of ECMO in the worlds during the past decades [1,2]. On the basis of the destination of oxygenated blood back, ECMO therapy could be subdivided into two basic modes: veno- venous (VV) and veno- arterial (VA). VV ECMO drains blood from a central vein and returns the oxygenated blood to another central vein, results in the venous blood refreshed by providing gas exchange [3]. VA ECMO drains blood from the central vein and pumps the oxygenated blood back to an artery, involves in raising both the arterial pressure and arterial oxygenation [3]. The indications for ECMO are still keep evolving, currently it is a standard therapy with clear indications includes: resuscitating patients from acute cardiogenic shock, cardiac arrest or cardiac failure; bridging to ventricular assist device (VAD) implantation or heart combined/or lung transplantation; post-transplant primary graft failure; any potentially reversible acute respiratory distress syndrome (ARDS)/ respiratory failure associated with pneumonia (viral or bacterial); providing time to identify other treatments may effective et al [4-6]. Both VV ECMO and VA ECMO can be used to treat refractory acute respiratory failure [7]. Receiving ECMO therapy may produce many complications such as limb ischemia, stroke, bleeding, infection, harlequin syndrome, severe damage of organs and cause poor prognosis [7]. Among all the complications, acute kidney injury (AKI) is the most frequently reported and related with the poorer prognosis and higher mortality [8-11]. The causes of AKI in ECMO patients are multifactorial and very complicated, including both patient and ECMO related factors [12]. Previously studies have compared the incidence and mortality

of AKI among patients requiring ECMO, or only reported AKI incidence between different ECMO modes via single-center record. However, it is lack of systematic study for the AKI incidence between patients on different ECMO modes. In addition, the incidence of severe AKI required renal replacement therapy (RRT) among patients receiving different types of ECMO remains unclear.

The aim of this meta analysis is to pool the available data to compare the AKI incidence among adult patients requiring different modes of ECMO.

2. Materials and Methods

2.1. Search Strategy

A systematic literature search was performed through PubMed, Web of Science, and Embase utilizing the search terms "acute kidney" OR "acute renal" AND "extracorporeal membrane oxygenation" OR "ECMO" OR "extracorporeal life support" OR "ECLS". Each study was evaluated for inclusion or exclusion for this analysis. No language or date restriction executed. This meta-analysis was conducted and reported according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA). (http://www.prismastatement.org/).

2.2. Study Selection

For the purpose of this analysis, eligible studies reported the incidence of AKI in adult patients underwent ECMO. Studies met the Population, Interventions, Comparison and Outcomes (PICO) criteria were included in the meta-analysis.

All the studies fulfilled the following criteria: original Case- control and cohort studies provided the data of AKI requiring/ not requiring RRT among adult patients (age$\geq$ 18 years) received ECMO with consideration of ECMO modes as intervention factor; case/ case series reports < 10 patients were excluded; no restriction on language/ year applied in full text written; duplicate articles were excluded.

2.3. Data Extraction and Study Quality

A data collecting spreadsheet (Microsoft Corporation, Redmond, WA) was established to extract the following data from each included study: the first author, publication year, country, study design, number of patients, patients age, ECMO modes, AKI definition, incidence of AKI requiring/ not requiring RRT, and mortality of ECMO related.

All studies were assessed for the quality using the Newcastle-Ottawa Quality Assessment Scale (NOS) including 3 aspects (selection, comparability and outcome/ exposure) and 8 items [13]. It ranges from 0 to 9 stars, studies with a score$\cong$ 6 were considered to have adequate methodological quality.

2.4. Statistical Analysis

Statistical analysis was performed using STATA statistical software (version 14.0; Stata Corp, College Station, TX). In the analysis, random effects models were applied to analyzed the outcomes of interest clinic features (dichotomous data); I^2 test was used to evaluate heterogeneity by Mantel-Haenszel method due to probability variance between observational studies; The pooled odds ratio (ORs) and their corresponding 95% confidence intervals (CI) were used to evaluate the relationship between ECMO modes and AKI incidence; Z test was used to assess the significance of the pooled ORs and graphically plotted using forest plots; Leave- one- out sensitivity and Influence analysis were performed to confirm consistency of the analysis. Finally, the potential of publication bias was evaluated by Egger's linear regression test, Beg's rank correlation test and the corresponding funnel plots. Statistically significant heterogeneity was defined as $\chi^2 P$ value < 0.05 or I^2 test $> 50\%$. Z test P value < 0.05 was considered statistically significant.

3. Results

3.1 Literature Search and study characteristics

The flow diagram of the studies with selection procedure and reasons for exclusion was shown in detail in Figure 1. A total of 4416 records were identified from 3 databases (PubMed, n= 1445; Web of Science, n= 617; Embase, n= 2354). After excluding duplicates (2000 records), 2416 titles and abstracts were screened manually for eligibility. Then in-vitro studies, focused on pediatric or neonate population, animal studies, case reports and review articles were excluded, 55 remaining articles were full-length reviewed for eligibility. The studies contained < 10 patients or unmatched interest outcomes were also excluded. 4 cohort and 3 case-control studies involving 1069 patients fulfilled the pre-specified criteria were included for the meta- analysis (Table 1). Six studies (85.1%) with a score≧ 6 were considered good quality according to the NOS criteria (Table 2 and Table 3). Three studies (42.9%) reported the outcomes with clearly defined AKI according to the guidelines proposed by RIFLE, AKIN, or KDIGO. Six (85.1%) studies defined ECMO supporting time as criteria for study exclusion or provided the patients supported time specifically.

Figure 1. The flow diagram for the meta- analysis.

Table 1. Patients characteristics

Authors	year	country	study design	Modes	Mean age (years)	No.of patients	AKI Definition	Time on support (days)
Aubron et al [14]	2013	Australia	cohort	VA-ECMO (67%) VV-ECMO (33%)	VA-ECMO 50 (43-59) VV-ECMO 35 (24-49)	158	required RRT	VA-ECMO 7 (5-10) VV-ECMO 10 (6-16)
Kielstein et al [15]	2013	Germany	case-control	VA-ECMO (45%) VV-ECMO (55%)	46	200	AKIN stage 3 for RRT	N/A
Lee et al [16]	2015	Korea	cohort	VA-ECMO (71%) VV-ECMO (29%)	Non-AKI 58.4 ±14.5 AKI 60.7 ±15.5	322	AKI stage 1-3 defined according to KDIGO	Non-AKI 5 ± 5.1 AKI 9.5 ± 10.1
Antonucci et al [17]	2016	Belgium	case-control	VA-ECMO (59%) VV-ECMO (41%)	48 (36–59)	135	according to AKIN	Non-AKI 8 (5-12) AKI 4 (3-8) AKI-CRRT 6 (4-10)
Silva et al [18]	2017	Portugal	cohort	VA-ECMO (94%) VV-ECMO (6%)	VA-ECMO 51.9 ±11.6 VV-ECMO 48.5 ±13.1	48	required RRT	VA-ECMO 5 ± 4.3 VV-ECMO 11 ± 6.4
Liao et al [19]	2018	China	case-control	VA-ECMO (94%) VV-ECMO (6%)	Non-AKI 45.58 ±15.80 AKI 45.35 ±17.93	170	according to KDIGO	Non-AKI 4 (2.2) AKI 5 (4.0)
Wu et al [20]	2018	Taiwan	cohort	VA-ECMO (39%) VV-ECMO (61%)	VA-ECMO 36 VV-ECMO 35	36	CRRT	Survivor 6 (3.2– 9.1) non Survivor 4.6 (1.5– 12.4)

Table 2. Newcastle-Ottawa Scale for assessing the quality of cohort studies

study	Selection				Comparability	outcome			scores
	Representativeness of the exposed cohort	Selection of the non exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts	
Aubron. 2013	★	★	★	★	★	★			6
Lee. 2015	★	★	★	★	★	★			6
Silva. 2017	★	★	★	★	★	★			6
Wu. 2018			★	★	★	★			4

Table 3. Results of quality assessment using Newcastle-Ottawa Scale for case-control studies

study	Selection				Comparability	Exposure			scores
	Is the case definition adequate?	Representativeness of the cases	Selection of Controls	Definition of Controls	Comparability of cases and controls on the basis of the design or analysis	Ascertainment of exposure	Same method of ascertainment for cases and controls	Non-Response rate	
Kielstein. 2013	★	★	★	★		★	★	★	7
Antonucci . 2016	★	★	★	★		★	★		6
Liao. 2018	★	★	★	★		★	★		6

3.2 Patient characteristics

In this study, 1069 patients receiving ECMO treatment between January 2005 and October 2016 were identified as being eligible for analysis. Of these patients, 65.9% (n= 705) received VA ECMO, 34.1% (n= 364) received VV ECMO; 68.4% (n= 482) patients developed AKI during VA ECMO, 58.5% (n= 213) patients developed AKI during VV ECMO; 26.2% (n= 185) patients developed AKI requiring RRT during VA ECMO, 33.5% (n= 122) patients developed AKI requiring RRT during VV ECMO.

3.3. Incidence of AKI in Patients Receiving Different Types ECMO

Overall, the incidence of AKI in patients receiving VA ECMO group was estimated 1.62 times higher (OR, 1.62; 95 % CI: 1.008- 2.593; I^2 = 53.3%, $\chi^2 P$= 0.045; Z= 1.99, P= 0.046) than the VV ECMO group (Figure 2). Subgroup analyses were performed according to different regions and study design method. The pooled estimated ORs by different region were Asian subgroup 0.85 (95% CI: 0.49- 1.46, I^2= 0.0%, $\chi^2 P$= 0.503, Z= 0.6, P= 0.552, Figure 2) and non-Asian subgroup 2.15 (95% CI: 1.38- 3.34, I^2 = 28.2%, $\chi^2 P$= 0.243, Z= 3.38, P= 0.001, Figure 2) respectively; The pooled estimated ORs by different study design method were cohort studies 1.54 (95% CI: 0.74- 3.2, I^2= 59.6%, $\chi^2 P$= 0.059, Z= 1.17, P= 0.243, Figure 3) and case- control studies 1.82 (95% CI: 0.98- 3.4, I^2= 43.5%, $\chi^2 P$= 0.17, Z= 1.89, P= 0.058, Figure 3) respectively.

```
        Study        |    OR      [95% Conf. Interval]      % Weight
--------------------+---------------------------------------------------
      non-Asian
Aubron  (2013)      |   1.335    0.688      2.592         18.41
Kielstein  (2013)   |   2.140    1.196      3.829         20.09
Antonucci  (2016)   |   2.542    1.194      5.413         16.61
Silva  (2017)       |   5.388    1.525     19.029          9.44
 Sub-total          |
  D+L pooled OR     |   2.145    1.378      3.340         64.56
--------------------+---------------------------------------------------
      Asian
Lee  (2015)         |   0.781    0.404      1.508         18.51
Liao  (2018)        |   0.640    0.180      2.273          9.39
Wu  (2018)          |   1.889    0.430      8.295          7.54
 Sub-total          |
  D+L pooled OR     |   0.848    0.492      1.460         35.44
--------------------+---------------------------------------------------
Overall             |
  D+L pooled OR     |   1.616    1.008      2.593        100.00
--------------------+---------------------------------------------------
```

Figure 2. The overall AKI incidence compared between VA ECMO patients and VV ECMO patients, the subgroup analysis showed according to different regions, and the corresponding forest plots; Using random effects model, odds ratios, Mantel- Haenszel method to perform the results.

```
          Study      |     OR     [95% Conf. Interval]     % Weight
--------------------+--------------------------------------------------
      cohort
Aubron  (2013)      |    1.335    0.688      2.592           18.41
Lee  (2015)         |    0.781    0.404      1.508           18.51
Silva  (2017)       |    5.388    1.525     19.029            9.44
Wu  (2018)          |    1.889    0.430      8.295            7.54
 Sub-total          |
  D+L pooled OR     |    1.544    0.745      3.203           53.90
--------------------+--------------------------------------------------
      case-control
Kielstein  (2013)   |    2.140    1.196      3.829           20.09
Antonucci  (2016)   |    2.542    1.194      5.413           16.61
Liao  (2018)        |    0.640    0.180      2.273            9.39
 Sub-total          |
  D+L pooled OR     |    1.825    0.980      3.399           46.10
--------------------+--------------------------------------------------
Overall             |
  D+L pooled OR     |    1.616    1.008      2.593          100.00
--------------------+--------------------------------------------------
```

Figure 3. The subgroup analysis showed according to different study design method and the corresponding forest plots; Using random effects model, odds ratios, Mantel- Haenszel method to perform the result.

3.4 Incidence of AKI Requiring RRT in Patients Receiving Different Types ECMO

The incidence of AKI requiring RRT in patients receiving VA ECMO group was estimated 1.69 times higher (OR, 1.69; 95 % CI: 1.02- 2.81; $I^2 = 47.1\%$, $\chi^2 P= 0.109$; $Z= 2.02$, $P= 0.044$) than the VV ECMO group (Figure 4).

```
           Study        |    OR      [95% Conf. Interval]     % Weight
--------------------+------------------------------------------------------
Aubron   (2013)     |   1.335      0.688      2.592            25.52
Kielstein  (2013)   |   2.140      1.196      3.829            28.36
Antonucci  (2016)   |   0.899      0.453      1.786            24.78
Silva   (2017)      |   5.388      1.525     19.029            11.96
Wu   (2018)         |   1.889      0.430      8.295             9.38
--------------------+------------------------------------------------------
D+L pooled OR       |   1.689      1.015      2.811           100.00
--------------------+------------------------------------------------------
```

Figure 4. The incidence of severe AKI requiring RRT compared between VA ECMO patients and VV ECMO patients the corresponding forest plots; Using random effects model, odds ratios, Mantel- Haenszel method to perform the result.

3.5 Sensitivity analysis

Sensitivity analysis was performed by Leave-one-out and Influence analysis, the stability and reliability of the results were confirmed as the pooled ORs were not substantially affected (Figure 5a and Figure 5b).

(a)

(b)

Figure 5. (a) Sensitivity analysis of AKI incidence for all the included studies; (b) Sensitivity analysis of severe AKI requiring RRT for the related included studies.

3.6 Assessment of Publication Bias

The Egger's linear regression test, Begg's rank correlation test and the corresponding funnel plots were used to report the incidence of AKI requiring/ not requiring RRT in patients receiving different

types ECMO. There was no evidence of publication bias or heterogeneity in the funnel plots of the interest outcomes among the included studies (all *P*> 0.05, Figure 6a and Figure 6b).

```
Egger's test
```

Std_Eff	Coef.	Std. Err.	t	P>|t|	[95% Conf. Interval]	
slope	.2406339	.7773777	0.31	0.769	-1.757679	2.238947
bias	.562698	1.908995	0.29	0.780	-4.344529	5.469925

(a)

```
Egger's test
```

Std_Eff	Coef.	Std. Err.	t	P>|t|	[95% Conf. Interval]	
slope	-.114374	.7921206	-0.14	0.894	-2.635255	2.406507
bias	1.589852	2.016288	0.79	0.488	-4.826876	8.006581

(b)

Figure 6. (a) The potential publication bias performed by Egg's test and Begg's test funnel plot for all the included studies; (b) The potential publication bias performed by Egg's test and Begg's test funnel plot for the related included studies.

4. Discussion

The population- based meta- analysis provided evidence that the incidence of AKI in patients who received VA ECMO was higher than the patients who received VV ECMO; The incidence of severe AKI requiring RRT in patients who received VA ECMO was higher than the patients who received VV ECMO.

According to the international voluntary registry Extracorporeal Life Support Organization (ELSO), the number of ECMO proliferated rapidly as the number of ECMO centers increased worldwide in the last decade [21-22] due to the indications expanded and technology improvement [23]. ECMO is not a routine therapy on account of the complicated technique and the sufficient resource demands. Although new ECMO treatment guidelines are developed to implement for the highest benefit- to- risk and benefit- to- cost ratios [24], patients who receive the treatment still exhibit a high mortality and may get various complications [25-27]. The complications of all ECMO technology are similar, they could be simply divided into related to ECMO equipment (oxygenator or pump malfunction, circuit or cannula issues et al.) and physiological complications (bleeding, haemolysis, infection and organs damage et al [28]). The incidence of complications that impact on long-term outcomes is varies and depends on the types of patients, primary disease progression, and evolving indications [4].

AKI is the most common complications associated with ECMO and that patients who received ECMO developing AKI would face poorer long- term outcomes and survivals compared to patients without ECMO related AKI [8-11]. The mechanisms of ECMO associated AKI are still remain unclear. ECMO triggers an acute inflammatory- like reaction, exposure to non-self membranes, primary disease progression, hemodynamics modified, damaged cardiac function, non- pulsatile blood perfusion, concomitant infection, exposure to diuretics or nephrotoxic agents, fluid overload, ischemia-reperfusion injury, release of inflammatory and oxidative stress mediators may contribute as factors [6,29-32] and cause prerenal AKI to develop to intrinsic AKI and cortical necrosis, which result in systemic inflammation and irreversible renal dysfunction. These are currently considered the major mechanisms in the pathophysiology of ECMO developed AKI [6].

The modes of ECMO chosen is determined by the types of organs supporting, the types of patients treated, and the desired outcome [4]. VA ECMO is performed for cardiocirculatory support with/ without respiratory failure [33]. It provides oxygen delivery and cardiac support simultaneously thus the working cardiac output is a mixture of non- pulsatile arterial flow from the ECMO pump and pulsatile arterial flow from the patient' s native cardiac output. On the other hand, VV ECMO is indicated to patients with severe, isolated, and refractory respiratory failures [33]. It provides oxygenated and decarboxylated blood, retains the native pulsatile cardiac output thus the alterations of

hemodynamics and renal perfusion may be less [6]. Several recent studies have shown that pulsatile flow may provide more beneficial and protective effects on microcirculation and renal perfusion than non-pulsatile flow [34-36], these findings were consistent with the difference of the working flow between modes of ECMO. In addition, the enhanced systemic oxygenation and reduced oxygen consumption may improve the renal metabolism in VV ECMO [39]. Considering primary diseases, the hemodynamic changes maybe more frequently occurred due to severe cardiac diseases and low cardiac output syndrome in VA ECMO. In summary, these maybe explanations for the higher AKI incidence in patients receiving VA ECMO than patients receiving VV ECMO.

Severe AKI requiring RRT among patients receiving ECMO is usually in the form of continuous renal replacement therapy (CRRT), although the reasons for initiating RRT may variable, a increased risk of hospital mortality among ECMO patients with severe AKI requiring RRT has already been proven [37-38]. As the primary diseases complicated and indications continuous updating, the study may play a role in preventing and early identifying the patients at potentially risk of ECMO related AKI when exercise the ECMO modes option.

The study has several limitations. Firstly, there are still few original studies to record (< 10) the different AKI incidence in patients receiving different ECMO modes. Second, there is statistical heterogeneity in the meta-analysis for AKI incidence. Potential origins for heterogeneity may be racial differences. As performed subgroup analysis according to ethnicity and study design, the result showed there was no heterogeneity in the Asian subgroup perhaps as this subgroup population is almost yellow. Lastly, although most of the patients developed ECMO- related AKI requiring RRT within 48h of ECMO insertion [15], long- term ECMO has been reported as an independent risk actor of AKI [40], due to the clinic data collection based on publications was limited, extra interested analysis could not performed (time spent, supporting organs, blood flow rate et al). Furthermore studies are required to demonstrate more associations of AKI indicators among the patients underwent the ECMO treatment.

5. Conclusions

In conclusion, there is a higher incidence of AKI and severe AKI requiring RRT in VA ECMO patients than the VV ECMO patients. More studies are needed to focus on the systematic clinic characteristics to predict and detect of AKI indicators among ECMO patients..

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Karagiannidis C, Brodie D et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. *Intensive Care Med*. **2016** May; 42(5): 889- 896.

2. Mao JPS, Sedrakyan A. The evolving use of ECMO: The impact of the CESAR trial. *Int J Surg*. **2016**; 35: 95- 9.

3. Kulkarni T, Sharma NS, Diaz-Guzman E. Extracorporeal membrane oxygenation in adults: a practical guide for internists. *Cleve Clin J Med*. **2016**; 83: 373- 384

4. Butt W, Maclaren G. Extracorporeal membrane oxygenation. *F1000Prime Rep*. **2013**; 5: 55.

5. Brodie D, Bacchetta M. Extracorporeal membrane oxygenation for ARDS in adults. *N Engl J Med*. **2011**; 365: 1905e14.

6. Chen YC et al. Acute kidney injury in adults receiving extracorporeal membrane oxygenation. *J Formos Med Assoc*. **2014** Nov; 113 (11): 778- 85.

7. Guglin M et al. Venoarterial ECMO for Adults: JACC Scientific Expert Panel. *J Am Coll Cardiol*. **2019** Feb 19; 73 (6): 698- 716.

8. Tsai TY, Chien H, Tsai FC, Pan HC, Yang HY, Lee SY, et al. Comparison of RIFLE, AKIN, and KDIGO classifications for assessing prognosis of patients on extracorporeal membrane oxygenation. *J Formos Med Assoc*. **2017** Nov; 116 (11): 844- 851.

9. Soliman IW, Frencken JF, Peelen LM, Slooter AJ, Cremer OL, van Delden JJ, et al. The predictive value of early acute kidney injury for long-term survival and quality of life of critically ill patients. *Crit Care*. **2016**; 20 (1): 242.

10. Ma P, Zhang Z, Song T, Yang Y, Meng G, Zhao J, et al. Combining ECMO with IABP for the treatment of critically Ill adult heart failure patients. *Heart Lung Circ*. **2014**; 23 (4): 363- 8.

11. Schmidt M, Bailey M, Kelly J, Hodgson C, Cooper DJ, Scheinkestel C, et al. Impact of fluid balance on outcome of adult patients treated with extracorporeal membrane oxygenation. *Intensive Care Med*. **2014**; 40 (9): 1256- 66.

12. Villa G, Katz N, Ronco C. Extracorporeal Membrane Oxygenation and the Kidney. *Cardiorenal Med*. **2015**; 6 (1): 50- 60.

13. Claudio Luchini et al. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. *World J Meta-Anal*. **2017** Aug 26; 5(4): 80- 84

14. Cecile Aubron et al. Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study. *Critical Care*. **2013**, 17: R73

15. Jan T. Kielstein et al. Renal function and survival in 200 patients undergoing ECMO therapy. *Nephrol Dial Transplant*. **2013** Jan; 28: 86- 90

16. Lee SW et al. Risk Factors for Acute Kidney Injury and InHospital Mortality in Patients Receiving Extracorporeal Membrane Oxygenation. *PLoS One*. **2015** Oct 15; 10(10): e0140674.

17. Antonucci E et al. The Impact of Renal Failure and Renal Replacement Therapy on Outcome During Extracorporeal Membrane Oxygenation Therapy. *Artif Organs*. **2016** Aug; 40 (8): 746- 54.

18. Passos Silva M et al. Extracorporeal membrane oxygenation in circulatory and respiratory failure- A single-center experience. *Rev Port Cardiol*. **2017**; 36 (11): 833- 842.

19. Liao X et al. Analysis of the risk factors of acute kidney injury in patients receiving extracorporeal membrane oxygenation. *Clin Nephrol*. **2018** Oct; 90 (4): 270- 275.

20. Wu MY et al. Predictors of hospital mortality in adult trauma patients receiving extracorporeal membrane oxygenation for advanced life support: a retrospective cohort study. *Scand J Trauma Resusc Emerg Med*. **2018** Feb 8; 26 (1): 14.

21. Thiagarajan RR et al. Extracorporeal Life Support Organization Registry International Report 2016. *ASAIO J*. **2017**; 63: 60- 67.

22. Sauer CM, Yuh DD, Bonde P. Extracorporeal membrane oxygenation use has increased by 433% in adults in the United States from 2006 to 2011. *ASAIO J*. **2015**; 61:31- 36.

23. Shekar K, Mullany DV, Thomson B, Ziegenfuss M, Platts DG, Fraser JF. Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients: a comprehensive review. *Crit Care*. **2014**; 18 (3): 219.

24. Rosenberg AA et al. Prolonged duration ECMO for ARDS: Futility, native lung recovery, or transplantation? *ASAIO J*. **2013** Nov- Dec; 59 (6): 642- 50.

25. Gray BW, Haft JW, Hirsch JC, Annich GM, Hirschl RB, Bartlett RH. Extracorporeal life support: experience with 2,000 patients. *ASAIO J*. **2015**; 61 (1): 2- 7.

26. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, Patroniti N, Antonelli M, Pesenti A, Pappalardo F. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. *Crit Care Resusc*. **2013**; 15 (3): 172- 8.

27. Tsai CW, Lin YF, Wu VC, Chu TS, Chen YM, Hu FC, Wu KD, Ko WJ. SAPS 3 at dialysis commencement is predictive of hospital mortality in patients supported by extracorporeal membrane oxygenation and acute dialysis. *Eur J Cardiothorac Surg*. **2008**; 34 (6): 1158- 64.

28. Millar JE et al. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. *Crit Care*. **2016** Nov 28; 20 (1): 387.

29. Hamdi, T.; Palmer, B.F. Review of Extracorporeal Membrane Oxygenation and Dialysis-Based Liver Support Devices for the Use of Nephrologists. *Am J Nephrol*. **2017**, 46, 139- 149.

30. Kilburn, D.J.; Shekar, K.; Fraser, J.F. The Complex Relationship of Extracorporeal Membrane Oxygenation and Acute Kidney Injury: Causation or Association? *BioMed Res Int*. **2016**, 1094296.

31. McDonald, C.I.; Fraser, J.F.; Coombes, J.S.; Fung, Y.L. Oxidative stress during extracorporeal circulation. *Eur J Cardiothorac Surg*. **2014**, 46, 937- 943.

32. Ikeda, M.; Prachasilchai, W.; Burne-Taney, M.J.; Rabb, H.; Yokota-Ikeda, N. Ischemic acute tubular necrosis models and drug discovery: A focus on cellular inflammation. *Drug Discov Today*. **2006** Apr; 11 (7-8): 364- 70.

33. Jeremie Reeb et al. Vascular access for extracorporeal life support: tips and tricks. *J Thorac Dis*. **2016** Apr; 8 (Suppl 4): S353- S363.

34. Adademir, T.; Ak, K.; Aljodi, M.; Elçi, M.E.; Arsan, S.; Isbir, S. The effects of pulsatile cardiopulmonary bypass on acute kidney injury. *Int J Artif Organs*. **2012**, 35, 511- 519.

35. Abu-Omar, Y.; Ratnatunga, C. Cardiopulmonary bypass and renal injury. *Perfusion*. **2006**, 21, 209- 213.

36. Santana-Santos, E.; Marcusso, M.E.; Rodrigues, A.O.; Queiroz, F.G.; Oliveira, L.B.; Rodrigues, A.R.; Palomo, J.D. Strategies for prevention of acute kidney injury in cardiac surgery: An integrative review. *Revista Brasileira Terpia Intensiva*. **2014**, 26, 183- 192.

37. Charat Thongprayoon et al. Incidence and Impact of Acute Kidney Injury in Patients Receiving Extracorporeal Membrane Oxygenation: A Meta-Analysis. *J Clin Med*. **2019** Jul; 8(7): 981.

38. Chen SW et al. Long-term outcomes after extracorporeal membrane oxygenation in patients with dialysis-requiring acute kidney injury: A cohort study. *PLoS One*. **2019**; 14(3): e0212352.

39. Askenazi DJ, Selewski DT, Paden ML, et al. Renal replacement therapy in critically ill patients receiving extracorporeal membrane oxygenation. *Clin J Am Soc Nephrol*. **2012**; 7: 1328- 36.

40. Lyu L et al. plasma free hemoglobin is a predictor of acute renal failure during adult venous-arterial extracorporeal membrane oxygenation support. *J Cardiothorac Vasc Anesth*. **2016**; 30: 891- 895